<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628743</url>
  </required_header>
  <id_info>
    <org_study_id>BN29854</org_study_id>
    <secondary_id>2015-001589-25</secondary_id>
    <nct_id>NCT02628743</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)</brief_title>
  <official_title>Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Effectiveness of 10 mg/kg BID Olesoxime in Patients With Spinal Muscular Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label, single arm study is to further evaluate long-term
      tolerability, safety and efficacy outcomes of olesoxime in participants with Spinal Muscular
      Atrophy (SMA) who previously participated in one of the following two clinical studies:
      TRO19622 CL E Q 1115-1 (NCT ID XXX, open-label Phase Ib, multicenter, single- and multiple-
      dose study) or TRO19622 CL E Q 1275-1 (NCT01302600, Phase II/III, adaptive, parallel-group,
      double blind, randomized, placebo-controlled, multicenter, multinational study).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2016</start_date>
  <completion_date type="Anticipated">May 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/f) of Olesoxime</measure>
    <time_frame>Pre-dose (Hour 0) at Weeks 1, 13, 26, 39, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady State (Vss/F) of Olesoxime</measure>
    <time_frame>Pre-dose (Hour 0) at Weeks 1, 13, 26, 39, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL Neuromuscular Module Version 3.0 Scale Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver PedsQL Generic Core Scales Version 4.0 Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver PedsQL Neuromuscular Module Version 3.0 Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Proxy EQ-5D-5L Questionnaire Index Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Proxy EQ-5D-5L VAS Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment: Caregiver (WPAI:CG) Questionnaire Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Generic Health Related Quality of Life: Short Form-36 Questionnaire Score</measure>
    <time_frame>Baseline (Week 1), Weeks 26, 52, 78, 104, 130; thereafter every 26 weeks up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Muscular Atrophy, Spinal</condition>
  <arm_group>
    <arm_group_label>Olesoxime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.
Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olesoxime</intervention_name>
    <description>Participants will receive homogeneous suspension of olesoxime.</description>
    <arm_group_label>Olesoxime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in the previous studies (TRO19622 CL E Q 1115-1 or TRO19622 CL E Q
             1275-1)

          -  For women of childbearing potential: agreement to use an acceptable birth control
             method during the treatment period and for at least 28 days after the last dose of
             olesoxime

        Exclusion Criteria:

          -  Female participants who are pregnant or lactating, or intending to become pregnant
             during the study

          -  Participants who, in the opinion of the investigator, are not suitable to participate
             in this open-label study

          -  Participants who have developed study drug hypersensitivity to olesoxime or one of the
             formulation excipients, including sesame oil

          -  Concomitant or previous participation in any investigational drug or device study
             within 90 days prior to screening

          -  Concomitant or previous participation in a survival motor neuron 2 (SMN2) targeting
             antisense oligonucleotide study within 6 months prior to screening

          -  History of human immunodeficiency virus infection, history of Hepatitis B infection
             within the past year, history of Hepatitis C infection which has not been adequately
             treated

          -  History of illicit drug or alcohol abuse within 12 months prior to screening, in the
             investigator's judgment

          -  Any serious medical condition or abnormality in clinical laboratory tests that, in the
             investigator's judgment, precludes the participant's safe participation in and
             completion of the study

          -  History or presence of an abnormal electrocardiogram (ECG) that is clinically
             significant in the investigator's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincare; Serv. Neurologie et Réanimation pédiatriques - Centre réf. neuromusculaire</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jeanne De Flandre; CIC pediatrique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital la Timone Enfants; Service de Pediatrie et Neurologie Pediatrique</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier, Hopital Gui de Chauliac; Service de Neuropediatrie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau; centre reference Maladies Neuro-musculaires Est parisien Neuropediatrie</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants; Unite de Neurologie Pediatrique</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen; Neuropädiatrie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Freiburg Zentrum für Kinder- und Jugendmedizin; Neuropädiatrie und Muskelerkrankungen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Von Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Salute Mentale</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto G. Gaslini; UOC Neurologia Pediatrica e Malattie Muscolari</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Cà Granda - Ospedale Maggiore Policlinico; Dip. di Salute Mentale</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA;NEMO (NEuroMuscular Omnicentre);Centro clinico - Fonda</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico G.Martino; Dip. Neurologia e Malattie neuromuscolari</name>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht; Polkliniek Neuromusculaire ziekten</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie; Klinika Neurologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery,; MRC Centre for Neuromuscular Diseases</name>
      <address>
        <city>London</city>
        <zip>WC1 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University &amp; The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

